Cohort profile of an early life observational cohort in China: Bone and MicroBiOme onset (BAMBOO) study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
17 May 2024
Historique:
medline: 18 5 2024
pubmed: 18 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

The Bone And MicroBiOme Onset (BAMBOO) study is an ongoing prospective observational cohort study conducted in Tianjin, China, aiming to determine age-appropriate trajectories for microbiome maturation and bone development and to identify the influence of dietary factors in the process. The recruitment started in September 2021 and was completed in February 2023. A total of 1380 subjects were recruited, 690 at birth (group 1) and 690 at 6 months of age (group 2). Groups 1 and 2 will be followed up for 12 months and 36 months, respectively. The age of the mothers was 31.1±3.7 (mean±SD), and the birth weight of infants was 3.3±0.5 kg with an incidence of caesarean section 50.4%. Food diary information of the first 100 subjects showed that 64 food items were introduced by 6 months. A pilot microbiome analysis revealed that at the species level, bacterial communities were composed of mostly Data collection will be completed in August 2025. Four stage-statistical analyses will be performed as the cohort reaches certain age thresholds before the final report. Analysis of BAMBOO data will be used to develop age-appropriate trajectories for microbiome maturation and bone development for children aged 0-3 years and investigate the contribution of dietary factors in the process. ChiCTR2100049972.

Identifiants

pubmed: 38760054
pii: bmjopen-2023-075417
doi: 10.1136/bmjopen-2023-075417
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e075417

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: XL, GZ, XZ, FR, LG, JC and YG are employed by BGI Research. MC, ND, SCM, MNH, NB, SKD and DW are employed by Nestle Research. The authors declared that they have no competing interests.

Auteurs

Jing Wang (J)

Tianjin Women's and Children's Health Center, Tianjin, China.

Chang Jiang (C)

Tianjin Women's and Children's Health Center, Tianjin, China.

Shuo Wang (S)

Tianjin Women's and Children's Health Center, Tianjin, China.

Lingyan Feng (L)

Tianjin Women's and Children's Health Center, Tianjin, China.

Yu Zhang (Y)

Tianjin Women's and Children's Health Center, Tianjin, China.

Yuanyuan Guo (Y)

Tianjin Women's and Children's Health Center, Tianjin, China.

Gongshu Liu (G)

Tianjin Women's and Children's Health Center, Tianjin, China.

Xi Li (X)

BGI Research, Wuhan, China.
BGI Research, Shenzhen, China.
Shenzhen Engineering Laboratory for Birth Defects Screening, BGl Research, Shenzhen, China.

Guohong Zhang (G)

BGI Research, Shenzhen, China.
Shenzhen Engineering Laboratory for Birth Defects Screening, BGl Research, Shenzhen, China.

Xiaowei Zhu (X)

BGI Research, Shenzhen, China.

Fangyi Ren (F)

BGI Research, Shenzhen, China.
China National GeneBank, Shenzhen, Guangdong, China.

Lingyao Guan (L)

BGI Research, Shenzhen, China.
China National GeneBank, Shenzhen, Guangdong, China.

Jiayu Chen (J)

BGI Research, Shenzhen, China.
China National GeneBank, Shenzhen, Guangdong, China.

Ya Gao (Y)

BGI Research, Shenzhen, China.
Shenzhen Engineering Laboratory for Birth Defects Screening, BGl Research, Shenzhen, China.

Mo Chen (M)

Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.

Noura Darwish (N)

Clinical Research Unit, Nestlé Research, Lausanne, Switzerland.

Sara Colombo Mottaz (SC)

Clinical Research Unit, Nestlé Research, Lausanne, Switzerland.

Marie Noelle Horcajada (MN)

Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.

Nicolas Bonnet (N)

Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.

Shaillay Kumar Dogra (SK)

Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.

Dantong Wang (D)

Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland dantong.wang@rdls.nestle.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH